---

CEO, CTMC

An accomplished leader in innovative biologics development and commercialization, Jason Bock helped form CTMC in 2022 as a joint venture between Resilience and MD Anderson Cancer Center to accelerate patient access to cell therapies by bridging cell therapy development and manufacturing with MD Anderson’s clinical trial capabilities. By collaborating with start-up biotech companies, Bock and CTMC streamline the cell therapy development process through the application of CTMC’s industrial and academic resources.

Under Bock’s leadership, CTMC has successfully navigated six novel cell therapies, including Obsidian Therapeutics’ TIL therapy OBX-115, and KSQ Therapeutics’ CRISPR/CAS9 TIL therapy KSQ-001EX, through investigational new drug clearance in just 18 months. 

“I am confident that over the coming years through both incremental and step change improvements, we will drive down the upfront costs and improve the availability of these desperately needed treatments.”